Clinical Trials Study
Copyright ©The Author(s) 2022.
World J Orthop. Jan 18, 2022; 13(1): 78-86
Published online Jan 18, 2022. doi: 10.5312/wjo.v13.i1.78
Table 1 Patient demographics at the time of the intervention (mean ± SD)
Parameter
Value
Age in yr (range)46.8 ± 14.5 (20–71)
Sex
Male, n (%)11 (46%)
Female, n (%)13 (54%)
Indication for injection
Osteoarthritis, n (%)20 (83%)
Kellgren-Lawrence Grade I (n)0
Kellgren-Lawrence Grade II (n)2
Kellgren-Lawrence Grade III (n)10
Kellgren-Lawrence Grade IV (n)8
(Osteo)chondral defect, n (%)4 (17%)
Prior ankle surgery
None, n (%)10 (42%)
Any, n (%)14 (58%)
Multiple, n (%)11 (46%)
Table 2 Procedure and follow-up (mean ± SD)
Parameter
Value
Accurate injections, n (%)21 (88%)
Accuracy by indication
Kellgren-Lawrence Grade I [n accurate (% of subset)]NA
Kellgren-Lawrence Grade II [n accurate (% of subset)]2 (100%)
Kellgren-Lawrence Grade III [n accurate (% of subset)]10 (100%)
Kellgren-Lawrence Grade IV [n accurate (% of subset)]5 (62.5%)
(Osteo)chondral defect [n accurate (% of subset)]4 (100%)
Accuracy by prior ankle surgery
None [n accurate (% of subset)]9 (90.0%)
Any [n accurate (% of subset)]12 (85.7%)
Multiple [n accurate (% of subset)]10 (90.1%)
Procedure time (min)17 ± 5
Completed follow-up, n (%)24 (100%)
Follow-up time (median days, IQR)14 (IQR, 14–16)
Complications, n (%)0 (0%)
Table 3 Patient reported outcome
Activity
Intervention
Follow-up
Difference (P value)
Willing to return, n (%)24 (100%)NANA
NRS of pain (0–10)
During procedure (median, IQR)1 (0–2)NANA
In rest (past 2 wk) (median, IQR)4 (2–7)3 (1–5)< 0.01
Walking (past 2 wk) (median, IQR)8 (6–9)7 (4–8)< 0.01